ATIP Avenir : Metabolism and cancer

Previous activities

Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of Paris XI, France. He was the recipient of the Roger Davis Award in 2010, finalist of the I.H. Page Young Investigator Award in 2011 and recipient of the EAS young Investigator award in 2013.

His research work at Columbia University has been mainly focused on two ATP-binding cassette transporters ABCA1 and ABCG1 that mediated the cholesterol efflux potential of HDL-cholesterol (good cholesterol). These transporters are central to the metabolic complications of the immune and hematopoietic systems not only in cancer but also in cardiometabolic diseases such as atherosclerosis. Therapies aimed at raising HDL-C are currently under Phase III clinical trials.

After a contribution to the development of new therapeutics for cardiovascular diseases at Pfizer, his current research interest as a group leader lies in immune and hematopoietic cell metabolism in diseases.

Our research program primarily focuses on the ‘Metabolism of the immune and hematopoietic systems in cancer and cardiometabolic diseases with the aim to gain insight in immune metabolic complications observed in these diseases. We are currently focusing on the identification of novel metabolic pathways that could act independently or in synergy on the metabolism of immune and hematopoietic systems in myeloproliferative disease, lung cancer and cardiometabolic diseases.

The team is dedicated to achieve a deeper understanding of the metabolism of the immune and hematopoietic system in cancer and cardiometabolic diseases with the hope of identifying new candidate targets for therapeutic interventions or new predictors of disease outcomes.

Link and contact

Advertising

Research Projects

Axe 1 : Metabolic abnormalities of the immune and hematopoietic systems associated to cancer cachexia. I. Role of metabolic pathways in cachexia associated to myeloproliferative disease and lung cancer. II. Identification of novel mutations in the cholesterol efflux transporter ABCA1 in myeloproliferative disorder.

These projects are supported by an European Marie Curie Career Integration Grant (CIG630926) and a national ATIP-AVENIR starting package.

Axe 2 : Metabolic abnormalities of the immune and hematopoietic systems in cardiometabolic diseases. II. Role of glycolytic pathways on cardiometabolic diseases II. Role of cholesterol efflux pathways on cardiometabolic diseases.

These projects are supported by a grant from the Agence Nationale de la Recherche (ANR) and the Fondation de France (FDF).

Team Publications